- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03465995
Test and Evaluation of Non-Invasive Neuro-Assessment Devices (NINAD: Neurokinetics, Inc, iPAS (NINADiPAS)
The long term goal for the Traumatic Injury Research Program (TIRP) is testing of novel devices for the identification and longitudinal assessment of traumatic brain injury (TBI). DoD (United States Department of Defense) has now tasked TIRP with the test and evaluation of these devices to assess reliability and validity. The objective of this effort is to test the reliability of the NKI, Inc, (NeuroKinetics, Inc) i-PAS device using a test/re-test protocol with healthy controls.
The research design is test/re-test, with three assessments obtained on three separate visits. This will allow the assessment of reliability of both the device and the measure(s) that are computed from the input signals. Participants will be Healthy Controls (HC) as defined in the inclusion exclusion section.
In this initial study, investigators will be administering standardized self-report instruments (Standard Form 36 - SF36, and Symptom Checklist 90r, or SCL-90r), standard three-lead EKG. In addition they will administer the NKI i-PAS specific protocol as delineated by NKI.
Study Overview
Status
Intervention / Treatment
Detailed Description
Traumatic brain injury is not only a significant medical and operational issue for the military but is a significant public health issue in the United States. The CDC reports that 1.4 million Americans sustain traumatic brain injuries each year. Of these 50,000 die, 235,000 are hospitalized and 1.1 million are treated and released from the emergency department. Among children fourteen years old and younger, there are an estimated 2685 TBI deaths per year, 37,000 hospitalizations and 435,000 emergency room visits.
Additionally, the Centers for Disease Control (CDC) also notes that TBI is significantly under-reported.
Traumatic brain injury is under detected. Neuropsychological evaluations are often nondisclosing The DoD has invested considerable funds in the development of devices for use in acute and chronic assessment of TBI. Unfortunately none of these devices have been tested systematically to establish reliability of the equipment, reliability of the signals obtained, or reliability of the measures derived from the signals obtained.
The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment.
It is important to distinguish between a device, a signal and a measure. As used here, the term device refers to a hardware technology used to obtain a signal. In the case of neurodiagnostic devices, the signal is usually a measurement of voltage as a function of time. Examples of signals pertinent to the present discussion include the electrocardiogram (providing an assessment of autonomic nervous system status), the electroencephalogram, evoked potentials, event related potentials, balance records and eye movement trajectories. A clear distinction must be drawn between a signal, typically a voltage record, and a measure which is a number that is computed from the voltage signal. Reliability and validity must be investigated separately for each measure For example, a dozen measures may be calculated from the same EEG voltage signal. The reliability and validity of each measure must be evaluated.
The objectives of this initial study are limited. The investigators address the question: are the measures obtained from the NeuroKinetics iPAS eye tracking system longitudinally stable in a clinically stable healthy participant? These measures are described in a subsequent section.
A single channel ECG will be acquired and measures of heart rate variability will be calculated from this signal. Measures of heart rate variability provide an indirect surrogate measure of complex multifactorial states that can have an impact on psychophysiological variables. Alterations of heart rate variability (HRV) are associated with pain, attention and cognitive function and fatigue, all of which can affect neurophysiological measures. High intra-individual variability in a test-retest study is a warning sign that between recording changes in the state of the participant rather than reliability failures in the eye tracking measure may be playing a role in low reliability.
Following consent, eligibility will be established based on head injury history, the score on the Symptom Checklist 90 (in the Supporting Documents file), the Short Form 36 (in the Supporting Documents file), and the Defense Veterans Brain Injury Center (DVBIC) Three Question Screening Tool.
The standard iPAS eye tracking evaluation as described below will be administered and the ECG will be recorded simultaneously during this process.
A second recording will be obtained within two to six days of the first recording.
A third recording will be obtained at approximately four weeks following the first recording.
This study will establish normal values of neuroassessment measures obtained from healthy controls and will be used to establish the statistical separation between healthy populations and clinical populations presenting neuropsychiatric disorders including TBI-positive patients.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Dmitry Mirochnitchenko
- Phone Number: 3018168462
- Email: dmitry.mirochnitchenko.ctr@usuhs.edu
Study Contact Backup
- Name: David Keyser, PhD
- Phone Number: 3012953467
- Email: david.keyser@usuhs.edu
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29409
- Recruiting
- The Citadel
-
Contact:
- Dena P Garner, Ph.D.
- Phone Number: 843-953-5060
- Email: garnerd1@citadel.edu
-
Contact:
- Christopher J Sole, Ph.D.
- Phone Number: 843-953-6386
- Email: csole@citadel.edu
-
Principal Investigator:
- Dena P Garner, Ph.D.
-
Sub-Investigator:
- Christopher J Sole, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female participants
- Between 18 and 55 years old
- In good general health. Good general health is operationalized for the purpose of this study by scores within one standard deviation of the mean in all eight sections of the short form 36.
- A normalized Global Severity Scale of less than or equal to 65 on the Symptom Checklist 90-R and subscale scores less than the cut scores indicating significant pathology.
Exclusion Criteria:
- Traumatic brain injury positive as determined by the DVBIC 3 Question Screening Tool.
- Any history of seizures or Central Nervous System (CNS) tumors
- A normalized Global Severity Scale of more than 65 on the Symptom Checklist 90-R or any subscale score indicating significant pathology.
- Scores greater than one standard deviation from the mean on all eight sections of the Short Form 36.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
NKI iPAS Diagnostic Protocol
Research participants who qualify for this study will put on EKG leads, and then a non-invasive device called iPAS, which will record heart rate and eye tracking data while participants perform a task on the screen of the device.
The testing session will not exceed 30 minutes.
Participants will take a total of 3 recordings over a period of roughly 5 weeks.
|
The NKI i-PAS: The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Unit performance reliability
Time Frame: Total participant time burden for the study is roughly 2 hours over the course of 5 weeks.
|
Due to the non-interventional nature of this study, no outcome data will be collected or tracked.
A database of baseline performance profiles will be developed for a group of healthy research participants.
The ultimate outcome of this study is a determination of reliability for the device.
|
Total participant time burden for the study is roughly 2 hours over the course of 5 weeks.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEM 91-2714
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traumatic Brain Injury
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueNot yet recruitingTBI (Traumatic Brain Injury)France
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
Queen Mary University of LondonCompleted
-
First Affiliated Hospital Xi'an Jiaotong UniversityXijing Hospital; Second Affiliated Hospital of Wenzhou Medical University; Central... and other collaboratorsRecruitingMTBI - Mild Traumatic Brain Injury | Moderate Traumatic Brain InjuryChina
Clinical Trials on NKI i-PAS Diagnostic Protocol
-
NeurolignUniversity of Miami; Allegheny Singer Research Institute (also known as Allegheny...Not yet recruiting
-
University of MiamiSyneos Health; NeurolignWithdrawnBrain Injuries, Traumatic
-
University of MiamiNeurolignRecruitingBrain Injuries | Brain Injuries, Traumatic | Traumatic Brain Injury | Mild Traumatic Brain Injury | Head InjuryUnited States
-
University of MiamiNeurolignTerminatedMild Traumatic Brain InjuryUnited States
-
Uniformed Services University of the Health SciencesU.S. Army Medical Research and Development CommandSuspended
-
University of MichiganNational Institute on Aging (NIA)Enrolling by invitationAlzheimer Disease | Mild Cognitive Impairment | Amnestic Mild Cognitive DisorderUnited States
-
William Beaumont HospitalsFoundation for Education and Research in Neurological EmergenciesCompletedTransient Ischemic AttackUnited States
-
Children's Hospital of Fudan UniversityChengdu Women's and Children's Central Hospital; Xiamen Children's Hospital; Kunming... and other collaboratorsRecruiting
-
Queen's University, BelfastBelfast Health and Social Care TrustCompleted
-
University of AarhusRecruiting